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Cross-presenting Xcr1+CD8α DCs are attractive APCs to target for therapeutic cancer
vaccines, as they are able to take up and process antigen from dying tumor cells for
their MHCI-restricted presentation to CD8T cells. To this aim, we developed fusion
proteins made of the Xcr1 ligand Xcl1 fused to an OVA synthetic long peptide (SLP) and
IgG1 Fc fragment. We demonstrated the specific binding and uptake of the Xcl1 fusion
proteins by Xcr1+ DCs. Most importantly, their potent adjuvant effect on the H-2Kb/OVA
specific T cell response was associated with a sustained tumor control even against
the poorly immunogenic B16-OVA melanoma tumor. The increased tumor protection
correlated with higher tumor infiltration of antigen-specific CD8+ T cells, increased
IFNγ production and degranulation potential. Altogether, these results demonstrate that
therapeutic cancer vaccines may be greatly improved by the combination of SLP antigen
and Xcl1 fusion proteins.
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INTRODUCTION
One of the key requirements for successful therapeutic cancer vaccinations relies on the ability to
target antigen to cross-presenting dendritic cells (DCs), a subtype of DCs which have the capacity
to shunt a proportion of internalized antigens from the endosomal compartments to the cytosol,
where they are processed for loading onto MHC class I molecules, resulting in efficient CD8+ T
cell responses (1). The chemokine receptor Xcr1 was shown to be the main marker characterizing
murine (2) as well as human cross-presenting DCs (3–5), and their superior cross-presentation
capacities of soluble and cell-associated antigens has been demonstrated in both mice (2, 6, 7)
and humans (3, 8). The Xcr1 chemokine receptor is co-expressed with CLEC9A (DNGR1) and
the ontogeny of Xcr1-positive DCs is strictly dependent on the transcription factor Batf3 (2, 9).
In mice, Xcr1 is expressed in ∼80% of lymphoid organ-resident CD8α+ DCs as well as in ∼80%
of migratory dermal CD103+ DCs (6). In humans, XCR1 is expressed in the majority of CD141+
CD11c+ blood DCs (3) and CD141hi tissue-residents DCs in dermis, liver, and lung (4, 5). Of note,
Xcr1 is co-expressed with DEC205 and CADM1 (5), which suggests the strong functional role of
Xcr1+ DCs in the cross-presentation of antigens derived from necrotic cells (10). Xcr1-expressing
DCsmigrate toward the chemokine Xcl1 secreted by activated CTLs, NK and NKT cells involved in
the cytotoxic response (3, 11). In contrast to many chemokine ligands that bind to several receptors,
Xcl1 binds exclusively to the Xcr1 receptor and is often co-secreted with Th1 profile cytokines,
such as IFNγ, MIP-1α, MIP-1β, and RANTES by activated murine NK cells, Th1 cells, and CD8+
T lymphocytes (12).
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Vaccinations involving synthetic long peptides (SLPs) have
given successful results in clinical studies with cancer patients
(13, 14), and are thought to avoid immunological tolerance
induced by exact length MHC class I-restricted peptides. Indeed,
unlike short synthetic peptides (SSP), SLPs require cellular
processing and cross-presentation, which avoids suboptimal
presentation by non-professional antigen presenting cells and
hence efficiently induce specific CTL responses (15, 16). SLPs are
generally 20–30 amino acids long and may harbor both MHC
class I and class II-restricted epitopes, resulting in enhanced
CTL expansion by triggering concomitant T helper responses.
In addition, antigens in the form of SLPs have been compared
against whole protein antigens in DC cross-presentation studies
and have been shown to be better processed resulting in improved
cross-priming of CD8+ T cell responses (17). Indeed, while whole
protein traffics only to endosomal compartments which primarily
promotes the priming of CD4+ T lymphocytes, SLPs traffic not
only to endosomes, but also to cytosol, allowing the priming of
both CD4+ and CD8+ T cell responses (18).
Antitumor immunity relies greatly on antigen cross-
presentation to allow debris from a dying tumor cell to be
processed and presented to CTLs. Nevertheless, cross-presenting
DCs are present at very low frequencies in human tissues, and
specific DC targeting strategies represent an important step in
optimizing cancer vaccines. Strategies recently used for targeting
antigen to DCs have included recombinant proteins resulting
from the genetic fusion of the antigen to mAbs that target DC
markers, such as DEC-205 (19) and CLEC9A (20–22), or to
chemokines (23).
In this context, we aimed to target to Xcr1+ DCs tumor
antigens in the form of SLP genetically fused or not to the
Xcl1 chemokine. In therapeutic tumor vaccination settings,
vaccination with the OVA SLP fused or not to Xcl1-Fc fusion
proteins enhanced CD8+ T cell responses and delayed B16.OVA
tumor growth. These results correlated with higher tumor
infiltration of antigen-specific CTLs as well as their increased
IFNγ production. These results demonstrate that therapeutic
cancer vaccines may be greatly improved by Xcl1-antigen
fusion proteins.
MATERIALS AND METHODS
Mice
Age and gender-matched C57BL/6 mice were purchased from
Envigo Laboratories (France). Batf3 knock out (KO) mice were
bred in our facilities under specific pathogen-free conditions.
All animal experimentation was performed according to ethical
approval from the Canton de Vaud authorities, Switzerland.
Veterinary authorization number VD2273.
Production of Xcl1-SLP muIgG1 Fc Fusion
Proteins
DNA sequences were inserted into the expression vector pMP-PB
(Excellgene) by In-Fusion technique (Clontech). DNA sequences
are shown in Supplementary Figure 1. Positive clones were
verified by DNA sequencing (Microsynth). Middle scale protein
production was performed in Chinese Hamster Ovary (CHO)
cells at the Laboratory of Cellular Biotechnology of EPFL,
Lausanne, Switzerland. Xcl1 fusion proteins were purified from
the supernatants of 7-day CHO cultures. Purification was
performed by affinity chromatography using Protein A resin
(GE Healthcare, cat no 17-1281-02). Proteins were eluted with
Glycine 0.1M pH 3.0 and dialyzed against PBS overnight. After
confirming their size and purity by SDS-PAGE, recombinant
proteins were passed through a Mustang Q membrane (PALL
Corporation) for endotoxin removal. Commercial Xcl1 was
purchased from Hölzel Diagnostika Handels GmbH, Germany
(item n◦50677-M08B).
In vitro Binding of Fusion Proteins to DCs
Spleens from naïve WT (C57BL/6) and Batf3−/− mice were
enriched for CD11c+ cells using CD11c (N418) microbeads
(cat number 130-052-001, Miltenyi Biotec). DC-enriched
suspensions from spleens of WT or Batf3−/− mice were
incubated with purified Xcl1-(OVA SLP)-Fc and Xcl1-Fc fusion
proteins at 37◦C for 35min. Cells were washed and binding of
fusion proteins was assessed using PE-conjugated anti-mouse
IgG1 antibody.
Chemotaxis Assay
Spleens from naïve WT (C57BL/6) mice were enriched for
CD11c+ cells using CD11c (N418) microbeads (cat number
130-052-001, Miltenyi Biotec). 1 x 106 cells (CD11c+ DC
purity of ∼50%) were resuspended in 0.1mL of chemotaxis
medium (RPMI1640, 1% BSA, 50µM ß-ME, 100µg/mL
penicillin/streptomycin) and added to the upper chamber of
a 24-transwell plate (with 8µm pore, Corning). In the lower
chamber, 0.5mL of chemotaxis medium was added, containing
either 250 ng/mL of commercial Xcl1, or 1,000 ng/mL of Xcl1-
(OVA SLP)-Fc or Xcl1-Fc fusion protein to have an equimolar
concentration of Xcl1 of 25 nM. After incubation for 2 h at
37◦C (5% CO2), bottom chambers were flushed with ice-cold
PBS containing 10mM EDTA and DCs were analyzed by FACS.
Cells were incubated for 5min on ice with 2.4 G2 to block Fc
receptors, Xcr1+ DCs were detected via incubation with Xcl1-
Fc protein (19 nM) for 30min at 37◦C, followed by washing and
staining with PE-conjugated anti-mouse IgG1 on ice for 30min.
Afterwards, surface markers antibodies were added in a mix, on
ice, for 30min. DCs were identified by first excluding CD3+
B220+ and CD11b+ cells and gating on CD11c+ CD8α+ cells.
In vivo Uptake of Alexa-488-Labeled Xcl1
Fusion Proteins
Alexa-488 dye (DY-490-NHS-Ester, from Dyomics, product
number 490-01) was resuspended in DMSO (the molar ratio
between 1mg of dye and 1mg of the Xcl1 fusion proteins
is 40.2, hence 40.2 µL of DMSO were added). The dye and
the 10x reaction buffer (1M Na Phosphate, 1.5M NaCl, pH
7.1) were added to the fusion proteins at a volume ratio of
1:10, and mix was incubated at room temperature for 1.5 h in
rotation and protected from light. Desalting columns (Zeba Spin
desalting column, Thermo Scientific, product number 89,890)
were washed with PBS by spinning 1,000 g for 2min. The labeled
proteins were added to the column and spun down. This step
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was repeated with the flow-through and final fusion proteins
concentrations were measured by BCA.
WT and Batf3 KO mice were injected intradermally in the
footpad with amix of 50µg of CpG and 6µg of Alexa 488-labeled
Xcl1-(OVA SLP)-Fc or Xcl1-Fc fusion proteins. Inguinal LNs
were harvested 16 h post injection for measurement of uptake in
different cell populations.
Peptide Solubilization
OVA SLP was solubilized with 10% sterile DMSO and
90% sterile PBS. The OVA SLP amino acid sequence is
KISQAVHAAHAEINEAGRESIINFEKLTEWT, which includes
the MHC class I-restricted epitope (in bold) and the MHC class
II-restricted epitope (in italic).
Immunizations
Vaccine formulations were prepared sterile, immediately before
injections. Mice were immunized with a volume of 30 µL
intradermally in the hind paw, on the ipsilateral side of
the tumors.
Tumor Engraftment
Mice were engrafted subcutaneously in the left flank either with
1 x 106 EG7 or 2 x 105 B16.OVA cells, or 1 x 105 B16.WT. Tumor
volumes were monitored every 2 days and were calculated using
the following formula: (length× width× thickness)/2.
Tumor Digestion: Tumors were harvested and digested using
the tumor dissociation kit fromMiltenyi Biotec (cat number 130-
096-730), according to manufacturer’s instructions. Cells were
then stained for flow cytometry.
Intradermal Vaccination
Mice received equimolar amounts of Xcl1 and OVA SLP antigen
injected intra-dermally in the footpad. Doses were the following:
20 µg of Xcl1-(OVA SLP)-Fc; or 17.6 µg of Xcl1-Fc + 1.3 µg of
free OVA SLP; or 1.3 µg of free OVA SLP + 5.9 µg free Xcl1; or
1.3 µg of free OVA SLP. All mice received 50 µg CpG-B (ODN
1826, U133-L01A; Trilink Biotechnologies).
Isolation of TILs
Tumors were digested as described above. Samples were then
diluted in 7mL of complete DMEM and added to 5mL of
Lymphoprep (cat number 1114547, Axis-Shield), followed by a
centrifugation of 1,800 rpm for 20min. Cells at the interphase
were collected, washed once, and plated in a 96-well plate for
in vitro peptide restimulation.
In vitro peptide restimulation and Intracellular Cytokine
Staining: TILs were incubated at 37◦C for 1 h with 10µM
SIINFEKL and anti-mouse CD107a (LAMP1) antibody-FITC
was also added (1/100) to wells. After 1 h, 1µg/mL GolgiPlug
and GolgiStop (BD biosciences) were added to the wells and TILs
were then incubated for a further 4 h at 37◦C before intracellular
cytokine staining. Cells were permeabilized and stained using
the Cytofix/Cytoperm kit (BD Biosciences), according to
manufacturer’s instructions and stained for intracellular IFNγ
and TNFα.
Calculation of the CD8/Tregs ratio: TILs were counted under
the microscope before surface/intracellular staining and FACS
acquisition. CD8/Treg ratio were calculated using the FACS
percentages of tetramer+ CTLs and CD4+ CD25+ FoxP3+, and
total TIL numbers.
Flow Cytometry
Blood and spleen samples were treated with Red Blood Cell
Lysis Solution (Qiagen) for 15min at 37◦C and 3min at
room temperature, respectively, before staining. LIVE/DEAD
Aqua fluorescent stain (Invitrogen) was used to discriminate
between live and dead cells. For tetramer staining, samples
were incubated with phycoerythrin (PE)-conjugated SIINFEKL-
H-2kb multimers (TC Metrix, Switzerland) for 35min at room
temperature. Samples were washed and incubated on ice for
30min with CD8α-PerCp Cy5.5 (clone 53.6.7–eBioscience),
CD3–PE Cy7 (clone 145.2C11–eBioscience), CD4–FITC (clone
GK1.5–produced in house, Ludwig Cancer Research). For
in vitro binding and chemotaxis assays the following antibodies
were used: IgG1–PE (clone A85-1–BD biosciences), B220–
Pacific blue (clone RA3-6B2 - LICR), CD8a–PerCp Cy5.5
(clone 53.6.7–eBioscience), CD3–PE Cy7 (clone 145.2C11–
eBioscience), CD11c–eFLuor 660 (clone N4/18–eBioscience),
CD11b–Alexa700 (clone M1/70–eBioscience), CD103–PE. Data
were acquired on a LSRII or LSRII (SORP) and FACS analyses
were done with Flow Jo software.
Statistical Tests
Statistical analyses were performed using GraphPad Prism
7 software (GraphPad Software, La Jolla, CA). Normally
distributed data were compared using one-way ANOVA or two-
way ANOVA (Figures 3A,B, 5A). Multiple comparisons were
corrected using Tukey tests. Normality was tested with a Shapiro-
Wilk test. On the graphs, data represent mean ± SE (∗p < 0.05;
∗∗p < 0.01; ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001).
RESULTS
Xcl1-(OVA SLP)-Fc Fusion Proteins Bind to
CD11c+ CD8α+ DCs and Induce
Chemotaxis of Xcr1+ DCs
With the aim to optimize synthetic long peptide (SLP) vaccines
by targeting the antigen to Xcr1+ cross-presenting DCs, a
recombinant fusion protein was produced with the ovalbumin
(OVA) SLP antigen fused to the Xcl1 chemokine, followed by
the murine IgG1 Fc for stability, dimerization and purification
purposes (Supplementary Figure 1). We opted for an Fc part
harboring the Asp to Ala mutation at amino acid position 265,
which prevents its binding to Fc receptors (24). A recombinant
protein lacking the OVA SLP antigen (Xcl1-Fc) was also
produced to evaluate the potency of Xcl1-mediated antigen
targeting (Figure 1A). The fusion proteins were tested for their
capacity to bind to CD11c+-microbeads purified CD8α+ DCs
from spleen (Figure 1B). CD11c+-enriched DCs from naïve WT
and Batf3−/− mice were incubated with the Xcl1-(OVA SLP)-
Fc fusion proteins at 37◦C, and specific binding was detected
with a fluorescently-labeled anti-IgG1-Fc antibody. Significant
binding of Xcl1 fusion proteins was seen in WT mice, when
gating on CD11c+ CD8α+DCs, while some heterogenous non-
specific binding was observed on the remaining CD8α+ cells
from Batf3−/− mice, which are deficient in Xcr1+ DCs (25)
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FIGURE 1 | In vitro characterization of Xcl1-(OVA SLP)-Fc fusion proteins. (A) Design of Xcl1-(OVA SLP)-Fc fusion proteins. The OVA SLP was fused to the
C-terminus of the murine Xcl1 amino acid sequence via an uncharged glycine/serine linker. The C-terminus of OVA SLP was connected to the murine IgG1
Fc, carrying the D265A mutation. (B) Gating strategy to identify CD8α DCs. (C) CD11c-enriched DCs from splenocytes of naive WT (C57BL/6) (black line) or Batf3−/−
(red line) mice were incubated with purified Xcl1-(OVA SLP)-Fc or Xcl1-Fc fusion proteins. Binding of XCL1 fusion proteins was assessed using a fluorescent
anti-mouse IgG1 antibody. Gray histograms represent control wells without fusion proteins. Each line represents a replicate. Results are representative of two
independent experiments. (D) In vitro chemotaxis assay performed with WT splenic DCs (enriched ∼50% CD11c+). Migration of DCs was assessed toward
Xcl1-(OVA SLP)-Fc fusion proteins at 25 nM (calculated based on the content of Xcl1 in the reagents). Results are expressed as the ratio between the number of
Xcr1+ and Xcr1− CD11c+ CD11b− DCs, which migrated toward Xcl1 fusion proteins or commercial Xcl1. Data are shown as mean ± SEM. Results are
representative of three independent experiments. *p < 0.05.
(Figure 1C). Similarly, the Xcl1 fusion proteins did not bind to
CD8α negative WT and Batf3 KO CD11c+ DCs (Figure 1C),
supporting the binding specificity to CD11c+ CD8α+ DCs, 80%
of which express Xcr1. To test whether the Xcl1-(OVA SLP)-
Fc fusion protein was capable of inducing chemotaxis of Xcr1+
DCs, trans-well migration experiments were performed with 1 x
106 CD11c+ enriched DCs in the upper chamber and medium
containing 25 nM of Xcl1 fusion proteins or commercial Xcl1
in the bottom well. After a 2-h incubation at 37◦C, analysis of
the bottom well-showed that Xcr1+ DCs had migrated between
2 and 4-fold more than Xcr1− DCs in all wells containing Xcl1
fusion proteins or free Xcl1 (Figure 1D). Overall, these data
demonstrated that the Xcl1-(OVA SLP)-Fc and Xcl1-Fc proteins
induced chemotaxis to a similar extent as the native chemokine
Xcl1 (Figure 1D).
XCL1-(OVA SLP)-Fc Fusion Protein Bind in
vivo to CD11c+ CD8α+ LN-Resident DCs
To investigate in vivowhich population of DCs will preferentially
bind the Xcl1-(OVA SLP)-Fc fusion proteins, Xcl1-Fc and Xcl1-
(OVA SLP)-Fc were fluorescently-labeled with Alexa 488 and
injected intradermally into WT or Batf3−/− mice. Skin draining
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LNs were harvested 16 h post immunization and analyzed for the
presence of the fusion protein in different subsets of CD11c+
DCs (Figure 2A). In WT mice injected with 6 µg of labeled
Xcl1-(OVA SLP)-Fc, about 10% of CD8α+ LN-resident were
Alexa 488 positive, compared to only 2% in Batf3−/− mice
(Figure 2B). Increased uptake of Alexa 488-labeled Xcl1-Fc by
WT CD8α+ was also observed, as shown by 18% compared to
4.7% in the same DC population in Batf3−/− mice. With regards
to CD103+ DCs, there was a tendency for increased uptake of
the fusion proteins by WT mice, although not significant due
to a large dispersion. Importantly, B cells, which are negative
for Xcr1 expression, did not bind the Xcl1 fusion proteins,
while <5% of phagocytic CD11b+ DCs, also negative for Xcr1,
became Alexa 488 positive for the Xcl1 fusion proteins both in
WT and Batf3−/−, indicating a non-specific uptake (Figure 2C).
Altogether, these results suggest that the Xcl1-(OVA SLP)-Fc
fusion proteins were preferentially and specifically taken up by
the Xcr1+ expressing CD8α+. Representative profiles of ex vivo
Alexa 488+-labeled cells are shown in Supplementary Figure 3.
Therapeutic Vaccines Involving Xcl1 Fusion
Proteins Lead to Regression of
OVA-Expressing Tumors
Given that cancer vaccines are ultimately evaluated for their
capacity to protect against tumors, the Xcl1 fusion proteins were
tested in therapeutic settings against the OVA-expressing EL-
4 lymphoma model (EG7). Gender and age-matched C57BL/6
mice were engrafted subcutaneously on day 0 with 1 x 106 EG7
cells (Figure 3A). On day 7, when tumors were established and
measurable, mice received an adoptive cell transfer of 105 OT-I
cells, followed on day 8 by intradermal vaccination with the
Xcl1 fusion proteins or with free OVA SLP +/- Xcl1. Except
for the untreated group, all mice received 50 µg of CpG-ODN.
In both cohorts vaccinated with the Xcl1-(OVA SLP)-Fc fusion
proteins, all tumors started to shrink 5 days post immunization.
In contrast, in mice receiving free OVA SLP + free Xcl1, tumor
volumes started to decrease only by day 15 but did not disappear,
while in mice receiving only the OVA SLP and CpG, only a delay
in tumor growth was obtained but no transient decrease of tumor
volumes (Figure 3A).
In view of the potent antitumor activity of Xcl1 fusion proteins
observed in the EG7 tumor model, we assessed the tumor
protective immunity of the Xcl1-mediated tumor vaccine in the
less immunogenic B16-OVAmelanoma tumor model. Mice were
grafted on day 0 with 2 x 105 B16.OVA cells and on day 7, when
all tumors were reaching an average volume of 30 mm3, mice
received an adoptive cell transfer of 105 naïve OT-I cells, followed
on day 8 by the intradermal vaccinations as described for the
EG7 challenge (Figure 3A). A significant tumor growth delay
was obtained in cohorts vaccinated with Xcl1-(OVA SLP)-Fc and
OVA SLP + Xcl1-Fc fusion proteins, as compared to mice not
receiving Xcl1 (OVA SLP and CpG only), while only a tendency
to a higher delay was observed against the OVA SLP + free Xcl1
cohort (Figure 3B). To assess a non-specific adjuvant effect of the
fusion proteins due to potential traces of endotoxin, two groups
were vaccinated with the Xcl1-Fc and Xcl1-(OVA SLP)-Fc fusion
proteins without CpG. However, both groups of mice showed fast
tumor growth (Figure 3B), confirming the adjuvant effect of Xcl1
fusion proteins. As seen in the blood on day 7 post-vaccination
in both EG7 and B16.OVA tumor challenge experiments, the
vaccination with Xcl1-(OVA SLP)-Fc fusion proteins plus CpG
led to similar expansions of OVA-specific CTLs, which was best
with Xcl1-(OVA SLP)-Fc, when compared to any other cohort,
likely resulting from the co-delivery of the antigen to cross-
presenting DCs via its fusion to Xcl1 (Figures 3C,D). Combined
immunization with the mixture of the fusion Xcl1-Fc protein and
the free OVA SLP + CpG still resulted in a significantly better
CTL expansion than in the group receiving free Xcl1 mixed with
the OVA SLP + CpG, which only showed a trend for higher
OVA-specific CTLs as compared to only OVA SLP+ CpG.
Tumors of Mice Vaccinated With Xcl1
Fusion Proteins Show Higher Infiltration of
OVA-Specific CD8+ T Cells Characterized
by an Increased Functionality
In order to dissect the mechanisms by which therapeutic
vaccinations using Xcl1 fusion proteins showed better tumor
control, B16.OVA tumors from mice immunized as described
in Figure 3B, were harvested 10 days post vaccination in
order to quantify TILs and characterize their functionality.
Frequencies of OVA-specific CD8+ T cells in the spleen
(Figure 4A) and in the tumors (Figure 4B, left panel) were
higher in the cohorts of mice vaccinated with Xcl1 fusion
protein as compared to the other cohorts. When normalized
by the tumor volume, mice vaccinated with the Xcl1 fusion
proteins also showed higher numbers of OVA-specific CD8+
T cells, as compared to cohorts vaccinated with free OVA SLP
+ CpG, with or without free Xcl1 (Figure 4B right panel).
Upon in vitro restimulation of tumor-infiltrating lymphocytes
(TILs) with SIINFEKL as illustrated in Figure 4C, we found
that cohorts vaccinated with Xcl1 fusion proteins showed
higher frequencies of IFNγ+ TILs than the other cohorts
(Figure 4D). Furthermore, increased frequencies of CD8+ TILs
expressing the lysosomal marker CD107a were also observed
(Figure 4E), associated with higher CD107a mean fluorescence
intensity (data not shown), indicative of increased degranulation
capacity. Altogether, these results suggest not only a higher
frequency but also a higher functionality of CTLs within
tumors of mice vaccinated with Xcl1-OVA SLP-Fc or Xcl1-Fc +
free OVA SLP.
Immunization With Xcl1 Fusion Proteins
Generates an Endogenous OVA CD8+ T
Cell Response as Efficient as Upon OT-1T
Cell Transfer
To be closer to a clinical situation, we wanted to assess the
tumor protection capacity of the Xcl1 recombinant proteins in
therapeutic vaccinations without OT-1 adoptive cell transfer.
To this aim, C57BL/6 mice were grafted s.c. with 2 x 105
B16.OVA melanoma cells as described in Figure 3. Mice were
vaccinated 3 days later, when tumors were all visible in the
flank of the mice. As in the previous experiment involving
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FIGURE 2 | In vivo uptake of Xcl1-(OVA SLP)-Fc in skin draining LN. WT and Batf3 KO mice were injected intradermally in the footpad with a mix of 50 µg of CpG and
6 µg of Alexa 488-labeled Xcl1-(OVA SLP)-Fc or Xcl1-Fc fusion proteins. Inguinal LNs were harvested 16 h post injection and the uptake of labeled fusion proteins was
measured in different populations of APCs, (A) gating strategy for identifying CD103+ and CD8α subtypes in CD11c+B220negDCs isolated from inguinal LNs.
(B) Uptake of labeled Xcl1-fusion proteins by CD8α DCs (left), CD103+ DCs (right), and (C) B220+ B cells (left), and CD11b macrophages (right). Data are shown as
mean +/- SEM (n = 3–4 mice/group). Results are representative of two independent experiments. ***p < 0.001, ****p < 0.0001.
OT-1T cell transfer, mice vaccinated with Xcl1-(OVA SLP)-
Fc fusion protein showed better control of B16.OVA tumor
growth, compared to other cohorts (Figure 5A). Mice were
bled 7 days after vaccination and the percentages of OVA-
specific CD8+ T cells followed the same pattern as seen upon
OT-1 cell transfer, with the highest percentages in the Xcl1-
(OVA SLP)-Fc and Xcl1-Fc + OVA SLP-immunized mice
(Supplementary Figure 2). Strikingly, when comparing tumor
growth kinetic with or without OT-1 T cell transfer (Figures 3A,
5A), the tumor control was quite similar, despite a 10-fold
lower frequency of endogenous OVA-specific T cells, as seen in
the blood on day 7 post vaccination (Supplementary Figure 2).
Moreover, when analyzing tumors 10 days post vaccination, we
observed that the frequency of OVA-specific CTLs infiltrating
the tumors of Xcl1-(OVA SLP)-Fc- and Xcl1-Fc + OVA SLP-
immunized mice was only 2–3 fold lower in the absence of
OT-1 cell transfer (Figure 5B), which confirmed their efficient
homing to the tumor, as compared to mice vaccinated with
free OVA SLP + free Xcl1. In addition, these settings also
revealed that the ratio between antigen-specific CD8+ T cells
and Tregs inside the tumor mass was 4-fold higher in Xcl1
fusion proteins-vaccinated cohorts when compared to mice
vaccinated with free OVA SLP with or without free Xcl1
(Figure 5C). Representative profiles of the gating strategy for
identifying T regs and OVA-specific CTLs are shown in
Supplementary Figure 4.
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FIGURE 3 | Anti-tumor immunity upon Xcl1-(OVA SLP)-Fc therapeutic vaccinations in tumor bearing mice. (A) Tumor growth of the T lymphoma EL4-OVA cell line
(EG7) grafted s.c. on the flank of mice (1 x 106 cells), followed on day 7 by the i.v. transfer of 105 OT-I cells and on day 8 by i.d. vaccination on the left foot (arrow).
Cohorts of mice received equimolar amounts of Xcl1 and OVA SLP antigen as described in Materials and Methods. All cohorts received 50 µg of CpG-ODN, except
the PBS control (B) Tumor growth of B16.OVA tumors engrafted s.c. on the flank of mice (2 x 105 cells), followed on day 7 by the i.v. transfer of 105 OT-I cells and on
day 8 by i.d. vaccination on the left foot (arrow), as described in (A). Graphs represent tumor kinetic as the mean of tumor volume of 6 mice per group ± SEM. n = 6
(except in groups with only fusion protein where n = 3). Results are representative of three independent experiments. (C) Frequencies of H-2Kb/OVA tetramer positive
CD8+ T cells in the blood 7 days after vaccination of EG7 and (D) of B16.OVA tumor bearing mice as described, respectively, in (A,B). Data are shown as mean ±
SEM (n = 6 mice/group). Results are representative of two independent experiments. **p < 0.01, ****p < 0.0001.
DISCUSSION
The goal of therapeutic cancer vaccines is to elicit a tumor-
specific T cell-mediated immune response, and their success will
rely on the use of adjuvants able to break immune tolerance, given
that in most cases tumor antigens are derived from self-antigens.
In that context, cross-presenting DCs are the APCs of choice,
as they are the only subtype of DCs capable of diverting part
of endocytosed antigens, such as peptides, from the endocytic
pathway to the cytosolic compartment where antigen is degraded
by the immunoproteasome before being loaded on to MHC class
I molecules for CD8+ T cell presentation (1). The aim of the
present study was to develop a strategy to harness these essential
cross-presenting DCs.
To do so, we took advantage of the uniquely selective
expression of the Xcr-1 chemokine receptor by cross-presenting
DCs, essential for their chemotaxis toward primed T cells at the
site of infection. We showed that fusion proteins of Xcl1, fused
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FIGURE 4 | Ex vivo function of TILs following Xcl1-fusion proteins vaccination. (A) Frequencies of OVA-specific CD8+ T cells in the spleens harvested 10 days post
vaccination of mice challenged with B16.OVA on day 0, adoptively transferred with OT-I cells on day 7 and vaccinated on day 8. Data is shown as mean ± SEM (n = 5
mice/group). Results are representative of two independent experiments. (B) Frequencies of H-2Kb/OVA tetramer positive CD8+ T cells present in the B16.OVA
tumors of vaccinated mice (left panel), and absolute number of SIINFEKL-specific CD8+ T cells per 5 mm3 of tumor mass (right panel). Data is shown as mean ±
SEM (n = 5 mice/group). Results are representative of two independent experiments. (C) Representative plots depicting the IFNγ content of CD3+CD8+ T cells
isolated from B16.OVA tumors 10 days post-vaccination and restimulated with or without SIINFEKL peptide. (D) Frequencies of IFNγ+ CD8+ T cells and (E) of
CD107a+ CD8+ T cells isolated from B16-OVA tumors. Data is shown as mean ± SEM (n = 5 mice/group). Results are representative of two independent
experiments. *p < 0.05, **p < 0.01, ***p < 0.001.
or not to a peptide antigen and dimerized on a Fc domain were
significantly internalized by lymph node-resident CD8α+ DCs,
and a trend for preferential uptake by migratory CD103+ DCs
was also observed [of which ∼80% express the Xcr1 chemokine
receptor (7)]. With regard to T cell antigen priming, we have
recently shown that the magnitude of tumor control depends
on the avidity of TAA recognition by tumor-infiltrating T cells
(26). In the present study, we have used the OVA antigen as a
surrogate neoantigen, since it is not subjected to central tolerance
and hence allows the priming and recruitment of high affinity T
cells to the tumor site. Indeed, therapeutic vaccination with the
Xcl1-(OVA SLP)-Fc fusion proteins was able to induce complete
tumor regression in the EG7.OVA model and a delayed tumor
growth in the more stringent B16.OVA melanoma model.
Previous studies have exploited Xcr1-antigen targeting either
in the context of Flu (27) or cancer vaccines. For instance,
Xcl1 or an anti-Xcr1 mAb have been fused to the full OVA
protein and tested in antitumor vaccinations, albeit in a tumor
prophylaxis setting (28). During the same year, another study has
targeted Xcr1+CD103+ DCs via laser-assisted intradermal ear
vaccination with Xcl1-OVA fusion protein on day 3 post tumor
graft (29). We now further demonstrate the vaccine potency of
Xcl1-antigen fusion proteins when injected on day 7 post-tumor
graft, when EG7 tumors or the more aggressive B16.OVA tumors
are fully established. Our study shows the monitoring of tumor
growth over a long period of time and, instead of LPS, our
vaccine formulation included the TLR9 ligand CpG-ODN, which
is a clinically accepted adjuvant (30). Moreover, our study shows
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FIGURE 5 | Effective therapeutic vaccinations with Xcl1-(OVA SLP) fusion proteins even in the absence of OT-1 T cell transfer. (A) B16.OVA tumor growth of C57BL/6
mice engrafted subcutaneously on the left flank with of 2 x 105 B16.OVA cells followed by intradermal vaccination on day 3. Data is shown as mean ± SEM (n = 5–6
mice/group). Results are representative of three independent experiments. (B) Frequencies of SIINFEKL-specific CD8+ T cells present in the B16.OVA tumors
harvested 10 days post vaccination. (C) Ratio of SIINFEKL-specific CD8+ T cells vs. Tregs within B16.OVA tumors. Data is shown as mean ± SEM (n = 5–6
mice/group). Results are representative of two independent experiments. *p < 0.05, **p < 0.01, ****p < 0.0001.
the extent to which vaccination impacts the immune response
within B16.OVA tumors, which showed a potent recruitment of
OVA-specific T cells to the tumor even in the absence of OT-1 T
cell transfer. In addition to their tumor targeting, these tumor-
specific CTLs also showed better effector functions, such as IFNγ
production and degranulation capacity.
Various strategies have used other surface markers to deliver
antigens to cross-presenting DCs, such as DEC205 (19) and
CLEC9A (20). Moreover, chemokine receptors common to
several subpopulations of DCs were also used to deliver antigens
fused to a chemokine such as the gp100 melanoma antigen
fused to CCL20 (31). The authors showed that such fusion
proteins are endocytosed via binding to the chemokine receptor
and are delivered to the cytosol for proteasomal processing,
resulting in their loading on MHC class I molecules in a TAP-1-
dependent manner, leading to potent tumor control. Alternative
strategies to target antigens to other subsets of DCs have also
been shown, for example by using glycoliposomes targeting DC-
SIGN+ DCs (32), or adenylate cyclase-based vector (CyaA) that
target CD11b+ DCs (33). Unfortunately, the large variability
between all these vaccination protocols does not allow evaluating
which DC marker is the most efficient for T cell priming.
In both of our tumormodels, the frequencies and functionality
of tumor infiltrating T cells as well as associated tumor control
were similar, whether the OVA SLP was fused with the Xcl1-Fc
or was co-delivered, which suggests that the signaling machinery
induced by the internalization of the cargo via the Xcr1
receptor was instrumental for efficient antigen internalization
and processing for MHC class I-mediated presentation. We can
also speculate that the intradermal delivery of the combined Xcl1-
Fc + OVA SLP vaccine formulation has reached the inguinal
lymph nodes in the form of aggregates, which were engulfed by
the same DCs. Additional experiments are required to clarify
that aspect. Of note, in our in vitro testing, both Xcl1 fusion
proteins showed similar binding to Xcr1+ DCs as well as similar
in vivo uptake by CD8α+ DCs. Importantly, vaccination with
Xcl1 fusion proteins did not only elicit a quantitatively higher
CTL response, but also a qualitatively increased recruitment
and functionality at the tumor site. In this context, it will be
important to evaluate if tumor control could be further enhanced
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by combining Xcl1-SLP-Fc vaccination with immune checkpoint
blockade, as demonstrated by us and others in pre-clinical and
clinical settings (26, 34–36). Lastly, it will be also important
to study the CD4+ T cell response to Xcl1 fusion proteins
vaccinations, which we failed to do in this work. Of note, Terhorst
et al. (29), who used laser-assisted delivery of Xcl1-OVA fusion
protein have reported CD4+ T cell responses, which may well-
participate in the efficient CD8+ T cell priming.
DCs are key players in initiating anti-tumor responses
and are considered as an essential target in the context
of cancer vaccinations (37). Some cancer vaccines directly
target DCs, such as Sipuleucel-T, which is the first FDA-
approved DC vaccine for the treatment of refractory
prostate cancer (38). Moreover, several clinical trials
are currently testing the allogenic GM-CSF-secreting
whole tumor cell vaccine GVAX in pancreatic cancer
patients (39). However, there is so far no DC vaccine
that specifically targets cross-presenting DCs in cancer
patients. A harmonization of all the strategies tested so far
would help in choosing the best DC-specific receptor(s)
for delivering tumor antigens to cross-presenting DCs.
Such DC targeting strategies may prove very attractive for
personalized cancer vaccines using tumor-derived neo-
antigens as identified by mass-spectrometry based antigen
discovery (40–42).
Our data demonstrate the applicability of Xcl1/Xcr1-mediated
DC vaccine for clinical development, given that Xcr1+ cross-
presenting DCs have also been well-described in humans.
Moreover, developing Xcl1-SLP-Fc fusion proteins as an off-
the-shelf DC vaccine might be a more economical and
easier alternative to ex vivo DC vaccines. Interestingly, the
efficacy of the Xcl1-Fc to promote effective targeting of the
synthetic long peptide immunogen as a mixture might greatly
facilitate the formulation of cancer type-specific, and neo-antigen
therapeutic vaccines.
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